ZNTLConferences•globenewswire•
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Sentiment:Negative (15)
Summary
(NASDAQ:ZNTL) SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences:
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 28, 2025 by globenewswire